Cancer-targeting siRNA delivery from porous silicon nanoparticles

Nanomedicine

Volumn 9, Issue 15, 2014, Pages 2309-2321

  Wan, Yuan ^a,b   Apostolou, Sinoula ^c   Dronov, Roman ^b   Kuss, Bryone ^c   Voelcker, Nicolas H ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

drug delivery; glioblastoma; MRP1; porous silicon nanoparticles; siRNA; ToF SIMS

Indexed keywords

MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NANOCARRIER; POROUS SILICON NANOPARTICLE; SILICON DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NANOPARTICLE; PRIMER DNA; SILICON;

APOPTOSIS; ARTICLE; BIODEGRADABILITY; CANCER GENE THERAPY; CANCER THERAPY; CELL ADHESION; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG UPTAKE; GENETIC TRANSFECTION; GLIOBLASTOMA; KIDNEY CLEARANCE; NONHUMAN; NONVIRAL GENE THERAPY; PARTICLE SIZE; PROTEIN EXPRESSION; ZETA POTENTIAL; BRAIN NEOPLASMS; CHEMISTRY; HUMAN; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; SCANNING ELECTRON MICROSCOPY; STATIC ELECTRICITY; TUMOR CELL LINE;

BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; GLIOBLASTOMA; HUMANS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; RNA, SMALL INTERFERING; SILICON; SPECTROMETRY, MASS, SECONDARY ION; STATIC ELECTRICITY;

EID: 84912089178     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.12     Document Type: Article

References (60)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
2. Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 126(2), 231-235 (2006).
3. Cioca DP, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. 10(2), 125-133 (2003).
4. McCarroll J, Kavallaris M. Nanoparticle delivery of siRNA as a novel therapeutic for human disease. Aust. Biochem. 43(3), 9-20 (2012).
5. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2(12), 711-719 (2006).
6. DeGorter MK, Conseil G, Deeley RG, Campbell RL, Cole SPC. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem. Biophy. Res. Commun. 365(1), 29-34 (2008).
7. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG, Cole SPC. The structure of the multidrug resistance protein 1 (MRP1/ABCC1): crystallization and single-particle analysis. J. Biol. Chem. 276(19), 16076-16082 (2001).
8. Denton BT, Sodhi MS. Introduction: 2008 Franz Edelman Award for Achievement in Operations Research and the Management Sciences. Interfaces 39(1), 2-5 (2009).
9. van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Müller M, Vellenga E. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin. Cancer Res. 4(7), 1727-1736 (1998).
10. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl Cancer Inst. 85(8), 632-639 (1993).
11. Burger H, Foekens JA, Look MP et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 9(2), 827-836 (2003).
12. Huang Y, Anderle P, Bussey KJ et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 64(12), 4294-4301 (2004).
13. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharmaceut. 6(3), 928-939 (2009).
14. Singh A, Boldin-Adamsky S, Thimmulappa RK et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68(19), 7975-7984 (2008).
15. Kato T, Natsume A, Toda H et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17(11), 1363-1371 (2010).
16. Mohri M, Nitta H, Yamashita J. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J. Neuro-Oncol. 49(2), 105-115 (2000).
17. Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, Cotter FE. In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. Int. J. Cancer 98(1), 128-133 (2002).
18. Kuss S, Cornut R, Beaulieu I, Mezour MA, Annabi B, Mauzeroll J. Assessing multidrug resistance protein 1-mediated function in cancer cell multidrug resistance by scanning electrochemical microscopy and flow cytometry. Bioelectrochemistry 82(1), 29-37 (2011).
19. Masiero M, Nardo G, Indraccolo S, Favaro E. RNA interference: implications for cancer treatment. Mol. Aspect. Med. 28(1), 143-166 (2007).
20. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
21. Na H-K, Kim M-H, Park K et al. Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 8(11), 1752-1761 (2012).
22. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem. Biol. 19(1), 60-71 (2012).
23. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J. 277(23), 4814-4827 (2010).
24. Sailor MJ, Wu EC. Photoluminescence-based sensing with porous silicon films, microparticles, and nanoparticles. Adv. Funct. Mater. 19(20), 3195-3208 (2009).
25. Park J-H, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat. Mater. 8(4), 331-336 (2009).
26. Bimbo LM, Sarparanta M, Makila E et al. Cellular interactions of surface modified nanoporous silicon particles. Nanoscale 4(10), 3184-3192 (2012).
27. Low SP, Voelcker NH, Canham LT, Williams KA. The biocompatibility of porous silicon in tissues of the eye. Biomaterials 30(15), 2873-2880 (2009).
28. Tasciotti E, Liu X, Bhavane R et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nano. 3(3), 151-157 (2008).
29. Sarparanta MP, Bimbo LM, Mäkilä EM et al. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 33(11), 3353-3362 (2012).
30. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv. Drug Deliver. Rev. 60(11), 1266-1277 (2008).
31. McInnes SJP, Voelcker NH. Silicon-polymer hybrid materials for drug delivery. Future Med. Chem. 1(6), 1051-1074 (2009).
32. Vasani RB, McInnes SJP, Cole MA, Jani AMM, Ellis AV, Voelcker NH. Stimulus-responsiveness and drug release from porous silicon films ATRP-grafted with poly(N-isopropylacrylamide). Langmuir 27(12), 7843-7853 (2011).
33. Xue M, Zhong X, Shaposhnik Z et al. pH-operated mechanized porous silicon nanoparticles. J. Am. Chem. Soc. 133(23), 8798-8801 (2011).
34. Tanaka T, Mangala LS, Vivas-Mejia PE et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 70(9), 3687-3696 (2010).
35. Xu R, Huang Y, Mai J et al. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 9(9-10), 1799-1808 (2013).
36. Xiao L, Gu L, Howell SB, Sailor MJ. porous silicon nanoparticle photosensitizers for singlet oxygen and their phototoxicity against cancer cells. ACS Nano 5(5), 3651-3659 (2011).
37. Hong C, Lee J, Zheng H, Hong S-S, Lee C. Porous silicon nanoparticles for cancer photothermotherapy. Nanoscale Res. Lett. 6(1), 321 (2011).
38. Secret E, Smith K, Dubljevic V et al. Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs. Adv. Healthc. Mater. 2(5), 718-727 (2012).
39. Kopermsub P, Mayen V, McInnes S, Voelcker NH. Fabrication and characterization of porous silicon nanoparticles for siRNA delivery. Presented at: 11th IEEE Conference on Nanotechnology. Portland, OR, USA, 830-832, 15-19 August 2011.
40. Torney F, Trewyn BG, Lin VSY, Wang K. Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat. Nano. 2(5), 295-300 (2007).
41. Li X, Xie QR, Zhang J, Xia W, Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 32(35), 9546-9556 (2011).
42. Alexis F, Pridgen E, Langer R, Farokhzad O. Nanoparticle technologies for cancer therapy. In: Drug Delivery. Schäfer-Korting M (Ed.). Springer, Berlin, Germany, 55-86 (2010).
43. Choi CHJ, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl Acad. Sci. USA 108(16), 6656-6661 (2011).
44. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nano. 2(4), 249-255 (2007).
45. Shah S, Liu Y, Hu W, Gao J. Modeling particle shape-dependent dynamics in nanomedicine. J. Nanosci. Nanotech. 11(2), 919 (2011).
46. Decuzzi P, Godin B, Tanaka T et al. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141(3), 320-327 (2010).
47. Halliwell CM, Cass AEG. A factorial analysis of silanization conditions for the immobilization of oligonucleotides on glass surfaces. Anal. Chem. 73(11), 2476-2483 (2001).
48. Xia B, Zhang W, Bao W, Dong C, Zhang J, Shi J. Photoluminescence enhancement of porous silicon particles by microwave-assisted activation. Phys. Status Solidi (A) 209(11), 2247-2250 (2012).
49. Bent SF. Organic functionalization of group IV semiconductor surfaces: principles, examples, applications, and prospects. Surf. Sci. 500(1-3), 879-903 (2002).
50. Hughes GA. Nanostructure-mediated drug delivery. Nanomed. Nanotech. Biol. Med. 1(1), 22-30 (2005).
51. Ashley CE, Carnes EC, Epler KE et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 6(3), 2174-2188 (2012).
52. Pan B, Cui D, Sheng Y et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res. 67(17), 8156-8163 (2007).
53. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9(1), 57-67 (2010).
54. Jackson AL, Linsley PS. Noise amidst the silence: off-target effects of siRNAs? Trends in Genet. 20(11), 521-524 (2004).
55. Azzam T, Domb AJ. Current developments in gene transfection agents. Curr. Drug delivery, 1(2), 165-193 (2004).
56. Hon NK, Shaposhnik Z, Diebold ED, Tamanoi F, Jalali B. Tailoring the biodegradability of porous silicon nanoparticles. J. Biomed. Mater. Res. A 100(12), 3416-3421 (2012).
57. Hom C, Lu J, Liong M et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 6(11), 1185-1190 (2010).
58. Xia T, Kovochich M, Liong M et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3(10), 3273-3286 (2009).
59. Beyerle A, Irmler M, Beckers J, Kissel T, Stoeger T. toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol. Pharmaceut. 7(3), 727-737 (2010).
60. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotech. 27(7), 643-651 (2009).